{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:20:17Z","timestamp":1789676417584,"version":"4.0.1"},"reference-count":38,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T00:00:00Z","timestamp":1468886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T00:00:00Z","timestamp":1468886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Cancer Care"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1111\/ecc.12541","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T11:46:46Z","timestamp":1468928806000},"page":"e12541","source":"Crossref","is-referenced-by-count":35,"title":["Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours"],"prefix":"10.1155","volume":"26","author":[{"given":"G.Z.","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Orthopedics; The First Affiliated Hospital; Shantou University Medical College; Shantou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics; The First Affiliated Hospital; Shantou University Medical College; Shantou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.X.","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Orthopedics; The First Affiliated Hospital; Shantou University Medical College; Shantou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Orthopedics; The First Affiliated Hospital; Shantou University Medical College; Shantou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.X.","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics; The First Affiliated Hospital; Shantou University Medical College; Shantou Guangdong China"},{"name":"Department of Orthopedics; The Affiliated Luohu Hospital; Shenzhen University; Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.Y.","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics; The First Affiliated Hospital; Shantou University Medical College; Shantou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.X.","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Orthopedics; The First Affiliated Hospital; Shantou University Medical College; Shantou Guangdong China"},{"name":"Department of Orthopedics; The Affiliated Luohu Hospital; Shenzhen University; Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.D.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Orthopedics; The First Affiliated Hospital; Shantou University Medical College; Shantou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2016,7,19]]},"reference":[{"key":"10.1111\/ecc.12541-BIB0001|ecc12541-cit-0001","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/ecc.12541-BIB0002|ecc12541-cit-0002","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1111\/ecc.12541-BIB0003|ecc12541-cit-0003","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1111\/ecc.12541-BIB0004|ecc12541-cit-0004","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1111\/ecc.12541-BIB0005|ecc12541-cit-0005","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1111\/ecc.12541-BIB0006|ecc12541-cit-0006","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/ecc.12541-BIB0007|ecc12541-cit-0007","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ctrv.2010.04.003","article-title":"Metastasis and bone loss: Advancing treatment and prevention","volume":"36","author":"Coleman","year":"2010","journal-title":"Cancer Treatment Reviews"},{"key":"10.1111\/ecc.12541-BIB0008|ecc12541-cit-0008","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group","volume":"14","author":"Conte","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12541-BIB0009|ecc12541-cit-0009","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1111\/ecc.12541-BIB0010|ecc12541-cit-0010","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"The Lancet"},{"key":"10.1111\/ecc.12541-BIB0011|ecc12541-cit-0011","first-page":"2587","article-title":"Prostate cancer cells-osteoblast interaction shifts expression of growth\/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts","volume":"9","author":"Fizazi","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/ecc.12541-BIB0501|ecc12541-cit-0501","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"10.1111\/ecc.12541-BIB0012|ecc12541-cit-0012","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: An analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Supportive Care in Cancer"},{"key":"10.1111\/ecc.12541-BIB0013|ecc12541-cit-0013","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1111\/ecc.12541-BIB0014|ecc12541-cit-0014","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1111\/ecc.12541-BIB0015|ecc12541-cit-0015","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S8756-3282(96)00285-2","article-title":"Clodronate decreases the frequency of skeletal metastases in women with breast cancer","volume":"19","author":"Kanis","year":"1996","journal-title":"Bone"},{"key":"10.1111\/ecc.12541-BIB0016|ecc12541-cit-0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jbo.2013.09.001","article-title":"Incidence, consequences and treatment of bone metastases in breast cancer patients-experience from a single cancer centre","volume":"2","author":"Kuchuk","year":"2013","journal-title":"Journal of Bone Oncology"},{"key":"10.1111\/ecc.12541-BIB0017|ecc12541-cit-0017","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1111\/ecc.12541-BIB0018|ecc12541-cit-0018","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/jco.2011.29.15_suppl.1534","article-title":"Prevalence of recognized bone metastases in the U.S. adult population","volume":"29","author":"Li","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12541-BIB0019|ecc12541-cit-0019","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2010.10.161","article-title":"Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis","volume":"48","author":"Lipton","year":"2011","journal-title":"Bone"},{"issue":"Suppl. 2","key":"10.1111\/ecc.12541-BIB0020|ecc12541-cit-0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1081\/CNV-120014886","article-title":"The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate","volume":"20","author":"Lipton","year":"2002","journal-title":"Cancer Investigation"},{"key":"10.1111\/ecc.12541-BIB0021|ecc12541-cit-0021","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1111\/ecc.12541-BIB0022|ecc12541-cit-0022","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO;2-D","article-title":"Oral bisphosphonates: A review of clinical use in patients with bone metastases","volume":"88","author":"Major","year":"2000","journal-title":"Cancer"},{"key":"10.1111\/ecc.12541-BIB0023|ecc12541-cit-0023","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney International"},{"key":"10.1111\/ecc.12541-BIB0024|ecc12541-cit-0024","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bjc.6600715","article-title":"Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer","volume":"88","author":"Noguchi","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1111\/ecc.12541-BIB0025|ecc12541-cit-0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ucl.2004.02.002","article-title":"The impact of osteoporosis in men treated for prostate cancer","volume":"31","author":"Oefelein","year":"2004","journal-title":"The Urologic Clinics of North America"},{"key":"10.1111\/ecc.12541-BIB0026|ecc12541-cit-0026","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"The Journal of Urology"},{"key":"10.1111\/ecc.12541-BIB0027|ecc12541-cit-0027","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.22504","article-title":"The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid","volume":"109","author":"Oh","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/ecc.12541-BIB0028|ecc12541-cit-0028","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"key":"10.1111\/ecc.12541-BIB0029|ecc12541-cit-0029","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer Journal"},{"key":"10.1111\/ecc.12541-BIB0030|ecc12541-cit-0030","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1111\/ecc.12541-BIB0031|ecc12541-cit-0031","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporosis International"},{"key":"10.1111\/ecc.12541-BIB0032|ecc12541-cit-0032","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1111\/ecc.12541-BIB0033|ecc12541-cit-0033","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/cncr.22678","article-title":"Economic burden of metastatic bone disease in the U.S","volume":"109","author":"Schulman","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/ecc.12541-BIB0034|ecc12541-cit-0034","first-page":"10","article-title":"Emerging therapeutic for the treatment of skeletal-related events associated with metastatic castrate-resistant prostate cancer","volume":"16","author":"Sieber","year":"2014","journal-title":"Reviews in Urology"},{"key":"10.1111\/ecc.12541-BIB0035|ecc12541-cit-0035","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12541-BIB0036|ecc12541-cit-0036","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Medical Care"},{"key":"10.1111\/ecc.12541-BIB0037|ecc12541-cit-0037","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/fampra\/18.6.565","article-title":"The association between funding by commercial interests and study outcome in randomized controlled drug trials","volume":"18","author":"Yaphe","year":"2001","journal-title":"Family Practice"}],"container-title":["European Journal of Cancer Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fecc.12541","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fecc.12541","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ecc.12541\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:10:22Z","timestamp":1671541822000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ecc.12541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,19]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"URL":"https:\/\/doi.org\/10.1111\/ecc.12541","archive":["Portico"],"relation":{},"ISSN":["0961-5423"],"issn-type":[{"value":"0961-5423","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7,19]]}}}